Alexion Pharmaceuticals, Inc. and Alexion Pharma International Sàrl received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the use of Soliris (eculizumab) as a treatment for patients in Japan with paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare, debilitating and life-threatening blood disorder defined by chronic red blood cell destruction, or hemolysis. Soliris, a terminal complement inhibitor, is the first therapy approved in Japan for the treatment of PNH. So...